Insider Holdings Update: Lund Kent Jeffrey’s Position at Selectis Health Inc.
On January 1, 2026, director Lund Kent Jeffrey disclosed that he continues to hold 15,992 voting common shares of Selectis Health Inc., a specialty healthcare real‑estate investment trust trading on the OTC Bulletin Board. The filing—form 3—shows no change in his ownership, indicating that he has not sold or purchased shares in the period covered by the disclosure. While the transaction itself is neutral, the context of recent insider activity and the company’s broader performance offers several clues about what this stance may signal to investors.
Current Insider Activity in Context
Jeffrey’s static position stands in contrast to the more dynamic activity seen among other insiders, most notably Baller Lance. Lance has executed a sizable purchase of 6,192 shares at $2.20 on December 18, 2025, boosting his holdings to 52,808 shares. This buy‑in, coupled with a sizable warrant position of 55,000, suggests that at least one insider is betting on a rebound in the stock’s price. In light of Selectis Health’s recent 52‑week low of $0.41 and the current trading level of $2.30, the buy‑in could reflect confidence that the share price is still undervalued relative to the firm’s asset base and upcoming asset sales.
Implications for Investors
For investors, Jeffrey’s unchanged stake may be interpreted as a signal of confidence in the company’s long‑term prospects. Directors who maintain or increase their holdings typically view the business as a viable investment, especially when the firm is navigating a volatile sector such as healthcare real‑estate. The lack of a sale also means there is no immediate pressure on the stock price from insider divestitures, which can sometimes trigger downward volatility.
Conversely, the mixed insider activity—steady holdings from some, aggressive buying from others—highlights a divided view among the leadership. If the market perceives that insiders are buying aggressively while others hold steady, it could hint at a belief that the company’s valuation is below its intrinsic value. For investors, this creates a potential buying opportunity, especially if the share price remains near the midpoint of its 52‑week range, suggesting a consolidation phase before a new directional move.
Looking Ahead
Selectis Health’s recent sale of the Sparta and Warrenton Transitional Care Facilities underscores a strategic focus on asset disposition and portfolio optimization. The company’s negative price‑earnings ratio of –8.622 and modest market cap of just over $7 million imply limited earnings but potential for asset‑value upside. If the company can generate cash from its real‑estate holdings and reinvest strategically, insider confidence may translate into a price appreciation, especially if the broader healthcare real‑estate market recovers.
In short, Lund Kent Jeffrey’s unchanged stake signals a steady, long‑term view from one key director, while the recent buying by other insiders suggests an optimistic outlook that could be capitalized on if the stock’s valuation improves. Investors should monitor further insider filings and the company’s asset‑sale pipeline to gauge whether this sentiment translates into tangible upside for the shares.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| N/A | Lund Kent Jeffrey () | Holding | 15,992.00 | N/A | Voting Common Shares |
| N/A | Lund Kent Jeffrey () | Holding | 3,261.00 | N/A | Voting Common Shares |
